CareDx Raises 2026 Revenue Outlook After Third-Quarter Sales Jump 39%

Aditi Sarkar

02 November 2026 10:39 PM AEDT

CareDx Raises 2026 Revenue Outlook After Third-Quarter Sales Jump 39%

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Third-quarter 2026 Revenue rose 39% to US$139.4 million, led by a 65% jump in testing services revenue.
GAAP Net Income increased to US$19.3 million, or US$0.35 per diluted share, from US$1.7 million a year earlier.
Testing Volume grew 51% to about 75,900 tests, including specialty oncology tests from the newly acquired Naveris business.
CareDx raised full-year 2026 adjusted EBITDA guidance to US$90 million to US$100 million from US$66 million to US$78 million.

CareDx, Inc. (NASDAQ:CDNA) lifted its full-year 2026 targets on 29 October 2026 after its first quarter including the Naveris specialty oncology Business delivered sharply higher revenue and profit, completing a reshaping of the transplant diagnostics company that began with the sale of its lab products unit.

The company now expects 2026 revenue of US$520 million to US$530 million, up from its prior range of US$490 million to US$500 million.

Testing Services Carry the Quarter

Total revenue for Q3 2026 reached US$139.4 million, up 39% from US$100.1 million. Testing services revenue rose 65% to US$119.2 million, including US$12 million of specialty oncology revenue and US$15 million of revenue relating to prior periods. Excluding prior-period revenue, testing services grew about 58%.

Test volume increased 51% to about 75,900. Patient and digital solutions revenue grew 31% to US$20.2 million, driven mainly by CareDx Pharmacy services. Product revenue fell to zero from US$12.5 million following the divestiture of the lab products business.

Profitability Improves Sharply

GAAP gross Margin was 71%, compared with 69% a year earlier, while non-GAAP gross margin reached 74%. Income from operations was US$8.1 million against a small loss in Q3 2025.

GAAP net income rose to US$19.3 million, or US$0.35 per diluted share, from US$1.7 million, or US$0.03. Non-GAAP net income was US$38.4 million, or US$0.70 per diluted share, and adjusted EBITDA doubled to US$30.5 million, a 22% margin. Free Cash Flow was US$11.1 million, compared with US$36.1 million a year earlier, and cash and cash equivalents stood at US$250.5 million on 30 September 2026.

Portfolio Reshaped Through Sale and Acquisition

On 30 June 2026, CareDx sold its Swedish Subsidiary CareDx AB and related kitted laboratory products Assets to Eurobio Scientific for US$171.7 million in cash, subject to adjustments. A day later, it completed the Acquisition of Naveris for about US$161.8 million in cash, with up to US$100 million more payable if revenue milestones for 2026 and 2027 are met.

Naveris's lead test, NavDx, is a blood-based assay that detects and monitors HPV-associated head and neck and anal cancers, including molecular residual disease surveillance after treatment. Naveris generated about US$35 million in revenue in 2025, and more than 130,000 NavDx tests have been commercially reported. NavDx is migrating to the CareDx billing platform.

Pipeline Milestones Set for 2027

President and Chief Executive John Hanna pointed to growth in transplant, progress in scaling specialty oncology and advances in cell therapy. CareDx is targeting a commercial launch of AlloHeme in Q1 2027 and broader availability of HistoMap Kidney in 2027, with both programs aiming for CLIA readiness by year-end. Management also expects 2026 adjusted EBITDA of US$90 million to US$100 million.

FAQs

Q: What does CareDx do?

A: CareDx provides molecular testing services and patient and digital solutions focused on transplant patients, and has expanded into specialty oncology through Naveris.

Q: What is NavDx?

A: NavDx is a blood-based test that detects and monitors HPV-associated head and neck and anal cancers, from diagnosis through post-treatment surveillance.

Q: What is CareDx's updated 2026 guidance?

A: Revenue of US$520 million to US$530 million and adjusted EBITDA of US$90 million to US$100 million.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.